Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma

Overexpression and/or hyperactivation of cyclin-dependent kinase 4 (CDK4) has been found in many types of human cancers, and a CDK4 specific inhibitor, palbociclib, has been recently approved by the FDA for the treatment of breast cancer. However, the expression and the therapeutic potential of CDK4...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochimica et biophysica acta. Molecular basis of disease 2018-05, Vol.1864 (5), p.1573-1582
Hauptverfasser:	Zhou, Yubing, Shen, Jacson K., Yu, Zujiang, Hornicek, Francis J., Kan, Quancheng, Duan, Zhenfeng
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Bone Neoplasms - drug therapy Bone Neoplasms - enzymology Bone Neoplasms - genetics Bone Neoplasms - pathology Cell cycle Cell Line, Tumor Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 4 - genetics Cyclin-Dependent Kinase 4 - metabolism G1 Phase - drug effects Gene Expression Regulation, Enzymologic - drug effects Gene Expression Regulation, Neoplastic - drug effects Humans Neoplasm Proteins - antagonists & inhibitors Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - enzymology Osteosarcoma - genetics Osteosarcoma - pathology Palbociclib Piperazines - pharmacology Pyridines - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!